Coherus Oncology (CHRS) EBIT Margin (2013 - 2026)
Coherus Oncology (CHRS) posted EBIT Margin of 293.67% for Q1 2026, up 18.4% sequentially from 359.9% in Q4 2025, and up 30424.0% YoY from N/an in Q1 2025.
Coherus Oncology (CHRS) EBIT Margin (2013 - 2026) Analysis & Trends
Coherus Oncology has reported EBIT Margin for 13 years, with the latest figure at 293.67% in Q1 2026.
- Quarterly EBIT Margin rose 30424.0% year-over-year to 293.67% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 366.55% (up 19311.0% YoY) and the FY2025 annual result came in at 429.51%, up 32706.0% from the prior year.
- EBIT Margin climbed to 293.67% in Q1 2026 per CHRS's latest filing, from 359.9% in the prior quarter.
- Over five years, EBIT Margin peaked at 42.92% in Q3 2023 and troughed at 2937.05% in Q1 2024.
- A 5-year average of 449.74% and a median of 293.67% in 2026 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2024 and 2025: EBIT Margin tumbled 272819 bps in 2024, then jumped 233914 bps in 2025.
- Over 5 years, EBIT Margin stood at 113.54% in 2022, then surged by 34 bps to 75.29% in 2023, then sank by 680 bps to 586.89% in 2024, then jumped by 39 bps to 359.9% in 2025, then increased by 18 bps to 293.67% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 293.67%, 359.9%, and 383.14% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.53 Bn | 130.68 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.34 Bn | 78.35 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.67 Bn | 59.48 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.03 Bn | 36.94 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.78 Bn | 27.47 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 27.81 Bn | 9.42 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.21 Bn | 26.05 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 26.99 Bn | 26.15 Bn | - | 19.75% |
| 10 | Coherus Oncology | 210.55 Mn | 105.25 Mn | 10.07 Mn | -225.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -225.98% |
| Mar 31, 2026 | -293.67% |
| Dec 31, 2025 | -359.90% |
| Sep 30, 2025 | -383.14% |
| Jun 30, 2025 | -443.59% |
| Mar 31, 2025 | -597.91% |
| Dec 31, 2024 | -586.89% |
| Sep 30, 2024 | -774.22% |
| Jun 30, 2024 | -384.87% |
| Mar 31, 2024 | -2,937.05% |
| Dec 31, 2023 | -75.29% |
| Sep 30, 2023 | -42.92% |
| Jun 30, 2023 | -58.83% |
| Mar 31, 2023 | -208.86% |
| Dec 31, 2022 | -113.54% |
| Sep 30, 2022 | -177.11% |
| Jun 30, 2022 | -73.17% |
| Mar 31, 2022 | -134.62% |
| Dec 31, 2021 | -53.91% |
| Sep 30, 2021 | -39.74% |